Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 22, 2024
Deals
Deals Report: Sionna looks to AbbVie for cystic fibrosis combos as Vertex-Orum strike degrader deal
Week's deals also include a radionuclide conjugate partnership between SK and Full-Life, and GT Apeiron hands off CDK7 to Exscientia
BioCentury | Mar 19, 2024
Deals
AZ deepens radiopharma commitment via $2B Fusion takeout
Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto
BioCentury | Nov 30, 2022
Deals
Nov. 29 Quick Takes: Horizon names three possible buyers, discloses early M&A talks
Plus: TCG, Lux lead $96M A round for Cajal and updates from Sana, X4, Roche, Ribon and more
BioCentury | Jun 6, 2020
Translation in Brief
Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more
BioCentury’s roundup of preclinical news
BioCentury | Jul 14, 2017
Strategy
Back to Ipsen’s roots
Why Ipsen is revving up clinical-stage BD and adding a venture fund
BioCentury | Aug 4, 2016
Distillery Techniques
Techniques: Neurotensin (NTS)-based PET imaging agents for diagnosing and monitoring treatment responses of neurotensin receptor 1 (NTSR1)-positive tumors
BioCentury | May 26, 2016
Distillery Therapeutics
Therapeutics: Neurotensin (NTS); neurotensin receptor 1 (NTSR1); proneurotensin
Items per page:
1 - 9 of 9